[Comment] Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?

The prognosis of metastatic renal cell carcinoma is poor, with a median 5-year survival of 9·5%.1 In patients with localised renal tumours, surgery remains the reference treatment, whereas radiotherapy plays a key role in the palliative care of patients with metastatic disease. However, during the past 20 years, a better understanding of biology has allowed targeted molecular therapies1 to emerge as a new standard of care in the metastatic setting. Regarding the role of radiotherapy in this setting, the sparing of surrounding healthy tissues has improved substantially thanks to the increasing use of stereotactic body radiotherapy (SBRT).